1521-0103/378/3/276–286$35.00
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

https://doi.org/10.1124/jpet.121.000639
J Pharmacol Exp Ther 378:276–286, September 2021

The Journal of PHARMACOLOGY And Experimental Therapeutics

P300 Participates in Ionizing Radiation–Mediated Activation of Cathepsin L by Mutant p53

Ya-jie Xiong,[1] Ying Zhu,[1] Ya-li Liu,[1] Yi-fan Zhao, Xiao Shen, Wen-qing Zuo, Fang Lin, and Zhong-qin Liang

Department of Pharmacology, Soochow University, Suzhou, China (Y.X., Y.L., Y.Zha., X.S., Q.Z., F.L., Z.L.), and Department of Pharmacy, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, China (Y.Zhu)

Received April 01, 2021; accepted June 28, 2021

ABSTRACT

Our previous studies have shown that cathepsin L (CTSL) is involved in the ability of tumors to resist ionizing radiation (IR), but the specific mechanisms responsible for this remain unknown. We report here that mutant p53 (mut-p53) is involved in IR-induced transcription of CTSL. We found that irradiation caused activation of CTSL in mut-p53 cell lines, whereas there was almost no activation in p53 wild-type cell lines. Additionally, luciferase reporter gene assay results demonstrated that IR induced the p53 binding region on the CTSL promoter. We further demonstrated that the expression of p300 and early growth response factor-1 (Egr-1) was upregulated in mut-p53 cell lines after IR treatment. Accordingly, the expression of Ac-H3, Ac-H4, AcH3K9 was upregulated after IR treatment in mut-p53 cell lines, whereas histone deacetylase (HDAC) 4 and HDAC6 were reciprocally decreased. Moreover, knockdown of either Egr-1 or p300 abolished the binding of mut-p53 to the promoter of CTSL. Chromatin immunoprecipitation assay results showed that the IR-activated transcription of CTSL was dependent on p300. To further delineate the clinical relevance of interactions between Egr-1/p300, mut-p53, and CTSL, we accessed primary tumor samples to evaluate the relationships between mut-p53, CTSL, and Egr-1/p300 ex vivo. The results support the notion that mut-p53 is correlated with CTSL transcription involving the Egr-1/p300 pathway. Taken together, the results of our study revealed that p300 is an important target in the process of IR-induced transcription of CTSL, which confirms that CTSL participates in mut-p53 gain-of-function.

SIGNIFICANCE STATEMENT

Transcriptional activation of cathepsin L by ionizing radiation required the involvement of mutated p53 and Egr-1/p300. Interference with Egr-1 or p300 could inhibit the expression of cathepsin L induced by ionizing radiation. The transcriptional activation of cathepsin L by p300 may be mediated by p53 binding sites on the cathepsin L promoter.

Introduction

Ionizing radiation (IR), which is one of the most important treatments for therapy of malignant tumors, has been in clinical use for almost a century. DNA of tumor cells is the major target of IR treatment. Nonetheless, a number of studies have indicated that, under certain conditions, tumor cells not only acquire radiation resistance but also exhibit greater invasiveness (Lee et al., 2017). However, the mechanisms responsible for the induction of radiation resistance in tumors and the biologic effects that increase invasiveness are still unclear.

It has been known for many years that mutation or deletion of the p53 gene is very common in cancer, with more than 50% of malignant tumors having this phenotype. Mutant p53 (mut-p53) not only fails to function in the same manner as wild-type p53 (wt-p53) but also acquires a range of new functions (gain-of-function mutations). This contributes to increased tumor invasiveness, metastasis, and resistance to conventional anticancer treatments in mut-p53 tumors. Previous research indicated that cathepsin L (CTSL) plays a key role in IR-induced radiation resistance and invasiveness of tumor cells (Fei et al., 2018). We also reported that IR could activate transcription of CTSL in mut-p53 tumor cells (Wang et al., 2019). CTSL can be activated by various different growth factors and even can be regarded as a tumor-related gene, or oncogene (Urbanelli et al., 2010). However, the transcriptional

This study was supported by the grants from the National Natural Science Foundation of China [Grants 81773768], the Priority Academic Program Development of the Jiangsu Higher Education Institutes (PAPD), Suzhou Science and Technology Development Project [SYSD2019175] and Municipal Health and Health Commission-Youth Project of "Promoting Health through Science and Education" Project of Suzhou (KJXW2018080).
The authors declare no competing interests.
[1]Y.X., Y.Zhu, and Y.L. contributed equally to this work.
http://dx.doi.org/10.1124/jpet.121.000639.

ABBREVIATIONS: ChIP, chromatin immunoprecipitation; CTSL, cathepsin L; Egr-1, early growth response factor-1; FITC, fluorescein isothiocyanate; HAT, histone acetyltransferase; HDAC, histone deacetylase; IR, ionizing radiation; mut-p53, mutant p53; PI, propidium iodide; wt-p53, wild-type p53; GOF, gain-of-function; p300, an important large protein molecule of the family of histone acetyltransferases; U251 and U87, human glioma cell lines; HT-29 and RKO, colon cancer cell lines; MDA-MB-468 and MCF-7, breast cancer cell lines; H1299, Non-small cell lung cancer cell lines; CREB, cyclic adenosine monophosphate response element binding protein; Ac-H3, Acetyl-histone H3; Ac-H4, Acetyl-histone H4; AcH3K9, Acetyl-histone H3 (Lys9); PBE, p53 binding region; C/EBPα, CCAAT/enhancer binding protein alpha; NF-Y, Nuclear Factor Y; NC, Negative control.

mechanisms controlling CTSL expression remain largely unknown, and there have been very few studies on relationships between mut-p53 and CTSL so far (Navab et al., 2008).

What is known is that the transcription factor CREB and early growth response factor-1 (Egr-1) are likely involved in transcriptional regulation of CTSL (Sriraman and Richards, 2004). Katara et al. (2010) reported that there are two p53 binding sites on the CTSL promoter. Their data showed that only wt-p53 could activate CTSL transcription by directly binding to the promoter of CTSL or indirectly inducing C/EBPα, the key transcription factor of CTSL. Our laboratory has investigated the effect of IR on CTSL expression and intriguingly found mut-p53 participated in this regulatory relationship. We recently reported that CTSL is highly expressed in wt-p53 cells when quiescent, but is expressed only at low levels in mut-p53 cells or in p53 null cells, which is consistent with the work of Katara et al. (Wang et al., 2016). However, our further studies found that IR significantly induced CTSL expression in mut-p53 cells.

The combination of the activity of mut-p53 with downstream transcription factor genes, such as Egr-1, and the upregulation of its expression is also an important factor in mut-p53 gain-of-function (GOF) (Sauer et al., 2010). Notably, Egr-1 is not only induced by IR, but also has a close relationship with mut-p53 (Orgad et al., 2005). It has been reported that Egr-1 can either promote or inhibit the proliferation of cells by activation of the transcription of its downstream genes (Peng et al., 2017). Our recent work has documented that mut-p53 upregulates transcription of CTSL by activating Egr-1 in lung cancer cells. Normally, the IR-induced apoptosis activation function of Egr-1 is mediated directly by wt-p53 (Zagurovskaya et al., 2009). Nevertheless, some studies showed that excessive activation of Egr-1 is an important activity of mutant p53 GOF (de Belle et al., 1999). Consequently, we hypothesized that mut-p53-mediated activation of CTSL by IR may be correlated with the excessive activation of Egr-1.

An important large protein molecule of the family of histone acetyltransferases (HATs), p300, mediates transcription by interacting with specific sequence activators and plays a key role in DNA impair, cell proliferation, and apoptosis (Magni et al., 2019). It was observed that p300, as an important acetyltransferase for wt-p53, could also form a large transcription-activating complex by interacting with mut-p53 and other transcription factors, activators, or protein factors. These may either up- or downregulate downstream genes, acting as a bridge between transcription factor and transcriptional protein complex (Barlev et al., 2001). Silverman et al. (1998) discovered that there is a binding site for Egr-1 on the promoter of p300, and Egr-1 could thus activate the transcription of this HAT. In addition, p300 was also found to inhibit the expression of C/EBPα in the liver (Breaux et al., 2015). Therefore, there might be a relationship between p300 and CTSL.

The purpose of the present study was to clarify the significance of mut-p53 in the transcriptional activation of CTSL induced by IR and to explore whether p300 is an important target in the CTSL transcription process induced by IR.

Materials and Methods

Cell Lines and Culture. Three pairs of tumor cell lines (human glioma cell lines U251 and U87, colon cancer cell lines HT-29 and RKO, breast cancer cell lines MDA-MB-468 and MCF-7) were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). U251, U87, HT-29, and RKO cells were cultured in high-glucose Dulbecco's modified Eagle's medium (HyClone, Los Angeles) containing 10% fetal bovine serum (Gibco, California). MCF-7 cells were cultured in Dulbecco's modified Eagle's medium (HyClone, Los Angeles) containing 10% fetal bovine serum (Gibco, California). The above five cells were maintained at 37°C in a humidified atmosphere containing 5% CO_2. MDA-MB-468 cells were cultured in Leibovitz's L-15 medium (HyClone, Los Angeles) containing 10% fetal bovine serum (Gibco, California) and cultured in a CO_2-free incubator at 37°C.

Clinical Tissue Samples. Colon cancer tissues (n = 10) and breast cancer tissues (n = 7) were collected from patients in the Affiliated Hospital of Jiangsu University (Zhenjiang, China). Glioma tissues (n = 6) were taken from the Suzhou Kowloon Hospital (Suzhou, China). None of the patients had received chemical prevention treatment before surgery. All samples were informed to the patients and given their informed consent before being obtained. At the same time, it is approved by the Ethics Committee of Affiliated Hospital of Jiangsu University and Suzhou Kowloon Hospital.

IR Condition and Antibodies. The cells were irradiated with Rad Source biologic X-ray irradiance (RS-2000 Pro, Rad Source, Inc.) under the condition of vertical X-ray irradiation, dose rate of 1.2 Gy/min, and total dose of 10 Gy. The antibodies to Ac-H3 (1:1000), H3 (1:1000), Ac-H4 (1:1000), H4 (1:1000), histone deacetylase (HDAC) 4 (1:1000), HDAC6 (1:1000), AcH3K9 (1:1000), and Flag (1:1000) were purchased from Cell Signaling Technology (Massachusetts). P300 (1:5000) was obtained from Bethyl Laboratories (Montgomery, TX). Egr-1 (1:1000) and CTSL (1:1000) were purchased from Abcam (Abcam, Massachusetts, UK). β-actin (1:1000) was obtained from MultiSciences (Lianke) Biotech (MultiSciences, Hangzhou, China).

Comet Assays. The slices were immersed in 1% normal melting point agarose (SolarBio, Beijing, China)/PBS for pretreatment and then dried into thin films. The appropriate number of cells were treated as needed, resuspended in PBS, and then quickly mixed with 0.8% low melting point agarose/PBS. A cover glass was added on each slide, and the slides were placed and cured according to the experimental requirements. The slides were immersed in alkaline lysis buffer (freshly prepared) at 4°C for 1 hour and kept away from light. Then, the slides were placed in an electrophoretic buffer (freshly prepared) at 4°C for 20 minutes. The samples were electrophoresed at 25 V and 300 mA at 4°C for 30 minutes. After electrophoresis, the slides were neutralized in Tris (0.4 mol/L, pH 7.5) for 5 minutes and then fixed with methanol for 10 minutes. Finally, the slides were stained with GelRed (Biotium, California), observed, and photographed under the fluorescence microscope.

Apoptosis Assay. Cell apoptosis was detected by the Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis detection kit (Beyotime, Jiangsu, China). The cells were cultured and treated as required in 6-well plates (NEST Biotechnology Co. LTD., Wuxi, China). At 24 hours after treatment, cells were collected and resuspended with 500 uL binding buffer, and then incubated with 5 μL Annexin V-FITC and 10 μL PI at room temperature for 15 minutes in the dark. At the end, apoptosis was analyzed by LSRII flow cytometry and FACSDiva software.

siRNA and Plasmid Transfection. siRNA for Egr-1 and p300 were purchased from GenePharma (GenePharma, Shanghai, China). Mutant p53 type and wild p53 type plasmids were purchased from Suzhou Golden Wisdom Biological Technology Co., Ltd. Cells were cultured in 6-well plates for 24 hours and transfected with either siRNA or plasmids using LipofectAMINE 3000 (Invitrogen) according to the manufacturer's protocol.

Western Blot Assay. The cells were cultured in 6-well plates (NEST Biotechnology Co. LTD., Wuxi, China) and then treated as required. The protein samples were then collected by lysis and centrifuge, separated by SDS-polyacrylamide gel electrophoresis, and transferred to nitrocellulose membrane in Bio-Rad (Hercules, CA). The

membranes were then incubated with primary antibodies at 4°C overnight, followed by incubation with secondary antibodies at room temperature for 1 hour in the dark. The blots were detected by Odyssey Infrared Imaging System (Li-COR Biosciences, Lincoln, NE), and Image J software was used to quantify the data.

Luciferase Reporter Assay. The luciferase reporter gene of p53 binding region (PBE) in the CTSL promoter was constructed by using pGL4 enhancer carrier from Suzhou Golden Wisdom Biologic Technology Co., Ltd. Cells were cultured with or without silencing of Egr-1/p300 expression and were transfected with pGL4-PBE-luciferase plasmid using LipofectAMINE 2000. After 48 hours, the cells were collected in the special lysate, added 50 uL β-gal substrate into 10 uL protein sample at 37°C in the dark, and added 10 uL luciferase substrates into another 10 uL protein sample using the Luciferase Reporter Assay System and Iuminometer to detect the luciferase activity before 30 minutes.

Chromatin Immunoprecipitation Assay. Cells were treated as indicated, and chromatin immunoprecipitation (ChIP) assay was conducted according to the manufacturer's protocol (Millipore). DNA was extracted by using the TIANGEN kit (TIANGEN, Beijing, China), and polymerase chain reaction was used to test the performance of ChIP. The gene of p53 was amplified by touch-down polymerase chain reaction. The sequences for the primers used for the ChIP assay were as follows: p53 forward primer 5′-CATGC CCGGG GCACC AGCTC-3′, p53 reverse primer 5′-TTCGC CTGAC TCTGC TTCTA-3′. The primers of p53 gene were synthetized by Shanghai Abm Co., Ltd. The amplification products were electrophoresed in 2.0% agarose gel and detected by Bio-Rad GelDoc XR System.

Immunohistochemical Staining. The Vectastain ABC kit (Vector) was used for immunostaining according to the instructions. In brief, the endogenous peroxidase activity of the slides was blocked with 3% hydrogen peroxide solution after deparaffinized, rehydrated, and treated with a citric acid solution for antigen repair. The slides were incubated in blocking solution (PBS, 3% bovine serum albumin), then incubated with primary antibody, followed by counterstaining with hematoxylin for nuclear staining. The negative control slides, without primary antibodies, did not exhibit nonspecific staining, and the slides were examined blind by two researchers.

Statistical Analysis. Data analysis was performed using GraphPad Prism 5 software. All experiments were independently repeated at least 3 times. The experimental results were expressed as the mean ± S.D. and Student's t test. $P < 0.05$ were considered statistically significant.

Results

The Effect of IR on CTSL Expression in Tumor Cells of Different p53 Status. Preliminary colony formation assays showed that the survival rate was significantly different after IR in different cell lines. For example, U87, RKO, and MCF-7 cells were obviously sensitive to IR. However, U251, HT29, and MDA-MB-468 cells showed a low sensitivity to IR and a strong survival rate (Fig. 1A). Correspondingly, comet assay showed that U87, RKO, and MCF-7 cells produced long comet tails after IR treatment, suggesting that DNA was damaged to varying degrees (Fig. 1B). Annexin V-FITC/PI apoptosis assay also showed that the apoptosis was not significantly increased after IR stimulation in U251, HT29, and MDA-MB-468 cells (Fig. 1C). Further study found that the differences in response to IR may be related to the status of p53 gene among these 3 pairs of tumor cell lines.

In addition, our previous studies have shown that CTSL is involved in the ability of tumors to resist IR (Hashimoto et al., 2006; Yang et al., 2015; Wang et al., 2019), therefore, we continued to investigate the correlation between p53 gene status and CTSL expression after IR stimulation. These cell lines are described in the *Materials and Methods* section. They were exposed to 10 Gy of X-rays. As is shown by Western blotting, levels of CTSL expression in mut-p53 cell lines were increased by IR, relative to wt-p53 cell lines (Fig. 2A). To further confirm the effect of IR on the regulation of the expression of CTSL in the mut-p53 cell lines U251, HT-29, and MDA-MB-468, we have generated a luciferase reporter vector containing a p53 binding site on the CTSL promoter and have transfected this vector into the cell lines. As shown in Fig. 2B, the activity of the luciferase reporter in U251, HT-29, and MDA-MB-468 cells was increased by IR, whereas this was not the case in wt-p53 cells. These results suggest that the IR-activated transcription of CTSL was mediated by increasing the activity of the p53 binding site on the CTSL promoter. Interestingly, we found that mut-p53 was selectively recruited to the relevant promoter region after IR treatment. This finding further confirmed the regulatory effect of mut-p53 for IR-induced expression of CTSL. Additionally, based on the sequence of the p53 binding regions on the CTSL promoter as reported in the literature, ChIP primers were designed and constructed. By means of this ChIP experiment (Fig. 2C), we found that the mut-p53 cells markedly increased CTSL expression after IR via promoter binding. This further documented the regulatory role of mut-p53 on CTSL expression after IR.

Egr-1 and p300 Are Involved in the IR-Induced Expression of CTSL. It has been reported that Egr-1 expression is increased in tumor cells transfected with mut-p53. Additionally, Egr-1 was significantly increased by IR in p53 knockout mice (Zhang and Wang, 2001; Rousselet et al., 2004). P300 is not only a downstream protein of Egr-1 but is also closely related to C/EBPα (Wang et al., 2019), which is a key regulatory factor of CTSL (Muller et al., 2009; Katara et al., 2010). To investigate this issue, we investigated Egr-1 and p300 expression in 6 cell lines. Egr-1 and p300 were both markedly increased by IR in mut-p53 cell lines compared with wt-p53 cell lines (Fig. 3, A and B).

Next, we investigated whether Egr-1 knockdown had any influence on IR-regulated p300 expression by transfecting Egr-1 siRNA (TABLE 1) into U251, HT-29, and MDA-MB-468 cells. After knocking down Egr-1, p300 expression was found to be significantly inhibited. More importantly, the IR-induced expression of CTSL was also abolished by knocking down Egr-1, compared with levels after IR of unmanipulated cells (Fig. 3C). Next, we determined that p300 knockdown (TABLE 1) also prevented the activation of CTSL transcription by IR (Fig. 3D). Correspondingly, p300 knockdown accompanied with IR caused serious DNA damage and reduced the survival rate in U251, HT-29, and MDA-MB-468 cells (Fig. 3, G and H). Furthermore, we assessed luciferase reporter activity of p53 binding sites on the CTSL promoter in Egr-1 and p300-siRNA-transfected cells. As shown in Fig. 3, E and F, the luciferase reporter activity in Egr-1/p300-siRNA-transfected cells did not change after IR. This indicated knockdown of both Egr-1 and p300 abolished the binding of mut-p53 to the promoter of CTSL.

IR Enhances the Acetylation Level of mut-p53 Cells and Mediates CTSL Expression. Previous studies demonstrated that p300, which is a broadly functional transcription cofactor, participates in the activation or inhibition of the transcription and expression of many genes by interacting with mut-p53 (Silverman et al., 1998; Barlev et al., 2001). As an



Fig. 1. The effect of IR in tumor cells of different p53 status. These 3 pairs of tumor cell lines were treated with different doses of IR, then cell survival was detected by colony formation experiment (A), DNA damage was detected by comet assay (B), and cell apoptosis was detected by Annexin V-FITC/PI apoptosis assay (C). (*P<0.05, **P<0.01, ***P<0.001 versus control).

important HAT, p300 catalyzes acetylation at multiple sites of lysine in histones. In our experiments, we found that IR induced H3 and H4 acetylation in mut-p53 cell lines (Fig. 4A). Using H1299 cells, we also found that IR significantly increased the acetylation level of H3 and H4 in p53 hot spots (p53-175, p53-248, and p53-273) relative to wt-p53–expressing H1299 cells, which is consistent with the results in endogenous mut-p53 cell lines (Fig. 4B).



Fig. 2. The effect of IR on CTSL expression in tumor cells of different p53 status. (A) Western blot of CTSL of whole cell extracts from U251, U87, HT-29, RKO, MCF-7, and MDA-MB-468 cells with or without IR treatment. β-actin was used as an internal control. (B) Luciferase reporter gene activity of p53 binding site on CTSL promoter in U251, U87, HT-29, RKO, MCF-7, and MDA-MB-468 cells with or without IR treatment. (*$P < 0.05$, **$P < 0.01$ versus control). (C) ChIP analysis of p53 binding site on CTSL promoter using p53 antibody in U251, U87, HT-29, RKO, MCF-7 ,and MDA-MB-468 cells with or without IR treatment.



Fig. 3. Egr-1 and p300 are involved in the IR-induced expression of CTSL. (A and B) Western blot of Egr-1 and p300 of whole cell extracts from U251, U87, HT-29, RKO, MCF-7, and MDA-MB-468 cells. β-actin was used as an internal control. (C and D) Western blot of Egr-1 and p300 of whole cell extracts from si-Egr-1/p300 RNA-treated U251, HT-29, and MDA-MB-468 cells with or without IR. β-actin was used as an internal control. (E and F) Luciferase reporter gene activity of p53 binding site on CTSL promoter in si-Egr-1/p300 RNA-treated U251, HT-29, and MDA-MB-468 cells with or without IR. (G) Colony formation experiment. (H) Comet assay. (*$P < 0.05$, **$P < 0.01$ versus control).



Fig. 4. IR enhances the acetylation level of mut-p53 cells and mediates CTSL expression. (A) Western blot of Ac-H3, H3, Ac-H4, H4, HDAC4, HDAC6, and AcH3K9 of whole cell extracts from U251, U87, HT-29, RKO, MCF-7, and MDA-MB-468 cells. β-actin was used as an internal control. (B) Western blot of Ac-H3, H3, Ac-H4, and H4 of whole cell extracts from H1299 (null of p53) and H1299 cell lines established with different p53 status plasmids. β-actin was used as an internal control.

HDACs modify histone tails through deacetylating amino-terminal lysine residues. This not only results in chromatin remodeling observed in numerous diseases, especially in tumorigenesis, but also counteracts the activity of HATs (Choudhary et al., 2009). After treating cells with IR, we also found that the expression level of HDAC4 and HDAC6 in

mut-p53 cell lines decreased compared with the decrease in wt-p53 cell lines (Fig. 4A). In addition, the expression of AcH3K9 was also assessed, and interestingly, we found that AcH3K9 in mut-p53 cell lines was notably induced by IR compared with wt-p53 cell lines. These results further indicate that IR improves the acetylation level of histones.

P300 Activates Transcription by Directly Acting on the CTSL Promoter. To further study the mechanism by which p300 is involved in IR-activated transcription of CTSL, we first conducted an immunoprecipitation experiment to determine whether p300 bound to the CTSL promoter and subsequently activated transcription by forming a complex with mut-p53. However, no binding of p300 and p53 was found in any of the 6 cell lines before or after IR, indicating that p300 did not combine with p53 to form a complex to activate transcription of CTSL. We further conducted ChIP assays on p300 and found that it bound to the p53-binding site on the CTSL promoter after IR only in mut-p53 cell lines (Fig. 5A). These results indicate that p300 can bind directly to the CTSL promoter and thus activate its transcription. Next, we conducted ChIP assays on p300-siRNA-transfected U251, HT-29, and MDA-MB-468 cells, and interestingly found that the IR-induced binding of mut-p53 to the CTSL promoter was abolished by knocking down p300 (Fig. 5B). Taken together, the above evidence points to a role for p300 as a positive regulator of CTSL transcription after IR in p53-mutant cell lines.

CTSL, Egr-1, and p300 Are Positively Correlated with Mutant p53 Status in Tissues Ex Vivo. Our laboratory has explored and reported on the relationship between CTSL expression level and glioma grade, and concluded that the strong expression of CTSL is not only a positive biomarker for these tumors but also participates in the invasion and migration of the tumor cells via various different mechanisms (Xiong et al., 2017; Fei et al., 2018). To further complement the study, we have now examined CTSL expression characteristics in clinical tumor tissues from other cancers. To this end, we have collected 10 colon tumor samples and 7 breast tumor samples as well as the corresponding paired normal tissue. We also collected clinical glioma samples harboring wild-type p53 ($n = 3$) and mutant p53 ($n = 3$).

By Western blotting assays, we found that CTSL is highly expressed in tumor tissue relative to the paired normal tissue in breast tumor samples (Fig. 6A). Additionally, Egr-1 was expressed more strongly in 50% of the breast tumor samples relative to the paired normal tissue. This result suggests that the level of CTSL expression is positively correlated with Egr-1 in colon cancer tissue. Furthermore, we sequenced the p53 gene in colon cancer samples to detect mutations and found that sample number 7 and number 8 harbored the p53-273 mutation, whereas the remaining samples possessed wild-type p53 or other non–hot spot mut-p53. To explore the relationship between CTSL, Egr-1 and p300 expression, we conducted immunohistochemical staining assays on mut-p53-273 and wt-p53 colon tumor tissue. As shown in Fig. 6B, CTSL, Egr-1, and p300 were all highly expressed in p53-273-mutated tissue relative to wt-p53 tissue. Interestingly, we found that CTSL located to the nucleus in mut-p53 tissue, which was consistent with our previous findings in lung cancer tissues. Additionally, the expression levels of CTSL, Egr-1, and p300 were all higher in breast tumor tissues than in paired normal tissue. Interestingly, CTSL, Egr-1, and p300 were more highly expressed in p53 mutant samples than wild-type p53 also in glioma samples.

Discussion

Based on the results of this study, we propose a new mechanism by which p300 is involved in the regulation of CTSL in mut-p53 cells. We mainly focus on findings that the IR-induced expression of CTSL is part of the mut-p53 GOF and



Fig. 5. P300 activates transcription by directly acting on the CTSL promoter. (A) ChIP analysis of p300 binding site on CTSL promoter using p300 antibody in U251, U87, HT-29, RKO, MCF-7, and MDA-MB-468 cells with or without IR treatment. (B) ChIP analysis of p53 binding site on CTSL promoter using p53 antibody in p300 knockdown U251, HT-29, and MDA-MB-468 cells with or without IR treatment.



Fig. 6. CTSL, Egr-1, and p300 are positively correlated with mutant p53 status in tissues ex vivo. (A) Western blot of CTSL, Egr-1, and p300 in clinical breast cancer and glioma tissues. β-Actin was used as an internal control. (B) Immunohistochemistry staining of CTSL, Egr-1, and p300 in wt-p53/mut-p53 clinical colon cancer and normal samples (arrows indicate the histologic features of the tissues).

reveal that p300 is an important target in the process of IR-induced transcription of CTSL.

To verify the relationship between mut-p53 and IR-induced expression of CTSL, we collected 3 pairs of tumor cell lines and quantified CTSL expression levels in these cells after IR. The results showed that CTSL was increased in mut-p53 cell lines, whereas it was almost unaltered in wt-p53 cell lines (Fig. 2). ChIP assays on tumor cells confirmed that mut-p53 activated transcription of CTSL by directly binding to the promoter of CTSL after IR. It was reported that p53 mutations fall into two main categories: DNA contact mutations and conformational mutations (Monteith et al., 2016; Duan et al., 2019). Although the p53 status of all 3 cell lines in our study (U251, HT-29, and MDA-MB-468) is DNA contact mutation, the mut-p53 of these cells was changed by IR to enable its binding to the CTSL promoter. This finding suggested to us that there might be some transcriptional cofactors assisting the binding capacity of mut-p53 to the CTSL promoter.

TABLE 1
The sequence of siRNA for transfection cells

siRNA		Base Sequence
Negative control (NC)	Sense	5′-UUCUCCGAACGUGUCACGUTT-3′
	Antisense	5′-ACGUGACACGUUCGGAGAATT-3′
si-Egr-1^{698}	Sense	5′-CCAACAGUGGCAACACCUUTT-3′
	Antisense	5′-AAGGUGUUGCCACUGUUGGTT-3′
si-Egr-1^{1508}	Sense	5′-GGCAUACCAAGAUCCACUUTT-3′
	Antisense	5′-AUUGUUGCUGUAUUUCUGGTT-3′
si-Egr-1^{1819}	Sense	5′-GCUGUCACCAACUCCUUCATT-3′
	Antisense	5′-UGAAGGAGUUGGUGACAGCTT-3′
si-p300^{728}	Sense	5′-GUCCUGGAUUAGGUUUGAUTT-3′
	Antisense	5′-AUCAAACCUAAUCCAGGACTT-3′
si-p300^{1807}	Sense	5′-GGACUACCCUAUCAAGUAATT-3′
	Antisense	5′-UUACUUGAUAGGGUAGUCCTT-3′
si-p300^{3797}	Sense	5′-CAUCACGGGUAUACAAAUATT-3′
	Antisense	5′-UAUUUGUAUACCCGUGAUGTT-3′

In previous studies, we found a direct binding relationship between the transcription factor Egr-1 and the CTSL promoter after IR. The results of the present study further confirm that the expression of Egr-1 significantly increased after IR treatment in mut-p53 cells (Fig. 3). Moreover, inhibition of Egr-1 efficiently abolishes the upregulation of CTSL by IR. Egr-1 is an important participant in the ability of wt-p53 to function in apoptosis, and could be induced by IR to inhibit the proliferation and growth of tumor cells by affecting the DNA-binding activity of downstream genes (Liu et al., 2001; Li et al., 2014; Peng et al., 2017). There would therefore be no clinical significance in inhibiting CTSL expression by Egr-1 knockdown directly. In the present study, we report that p300, a multifunctional acetyltransferase, plays an important role as a novel participant in the regulation of CTSL expression by mut-p53. It was previously reported that p300 is not only regulated by Egr-1, but also positively correlates with CEBP/α, which is a known regulatory factor of CTSL (Barlev et al., 2001; Breaux et al., 2015; Wang et al., 2016). Taken together, these data indicate that p300 is an important factor which must be taken into account when investigating the mechanisms regulating cathepsin L expression.

Di Agostino et al. (2006) confirmed that during DNA damage, the mut-p53/NF-Y complex had opposite effects on the transcription level compared with the wt-p53/NF-Y complex. Mut-p53 recruited p300 and caused abnormal transcription and cell cycle disorders of NF-Y target genes, whereas wt-p53 recruited HDAC1 and had an inhibitory effect on NF-Y target genes (Di Agostino et al., 2006). However, it is not clear in which opposing manner they recruit p300 or HDAC1, respectively. The mechanisms of these differential effects are thus still unclear. Our data showed that p300 was increased in mut-p53 cell lines after IR, and that inhibition of p300 significantly decreased the mut-p53–mediated upregulation of CTSL. The results of this experiment also led to the basic conclusion that mut-p53 cells could mediate transcriptional activation of CTSL by recruiting p300 after IR. In our experiments, we found that IR treatment increased the acetylation levels of H3, H4, and H3K9, but decreased histone deacetylase levels of HDAC4 and HDAC6 in mut-p53 cells. In addition, we established cell lines with different p53 states by using H1299 cells to verify the effect of IR on the acetylation of H3 and H4. The results showed that IR significantly increased the acetylation levels of H3 and H4 in mut-p53 cells (p53-175, p53-248, and p53-273), which is consistent with the results from endogenous mutant p53 cell lines. These results indicate that IR increases the acetylation level of histones in mut-p53 cell lines. Therefore, as a functional acetylated protein closely related to p53, p300 is recruited by mut-p53 under the influence of IR.

To further explore the mechanism by which p300 participates in the IR-regulated expression of CTSL, we conducted ChIP assays on cells of different p53 status, exposed or not exposed to IR. Interestingly, the results showed that p300 exhibited enhanced binding to p53 binding regions on the CTSL promoter after IR in mut-p53 cell lines. These results suggest that p300 activates transcription by directly acting on the CTSL promoter, and that the binding region for p300 on the CTSL promoter has a high degree of homology with p53 (Fig. 5). When p300 was silenced in p53 mutant cell lines, ChIP analysis revealed that the IR-induced enhanced binding of p53 to CTSL was eliminated, further emphasizing an important role of p300 in mediating transcriptional activation of CTSL in mut-p53 cells. Therefore, although p53 produced binding mutations in U251, HT-29, and MDA-MB-468 cells, the mut-p53 regained the ability to bind DNA with the help of Egr-1 and p300. More importantly, this study found that p300 regulated CTSL by binding to the p53 binding region after IR.

Moreover, our study further showed that the expression level of CTSL was higher in clinical colon and breast cancer tissues than in counterpart paired normal tissues. We also found that the expression levels of Egr-1 and p300 were positively correlated with CTSL in these cancer tissues (Fig. 6). Our previous work on lung cancer tissue found that the CTSL expression level was significantly higher in tumor tissue than in paired normal tissue, especially in p53-273 mutated tissue (Zhang et al., 2015; Wang et al., 2019). In the present study, we conducted p53 gene sequencing on 10 colorectal tumor tissues and 6 glioma tissues. Interestingly, in glioma, CTSL, Egr-1, and p300 were more strongly expressed in p53 mutant samples than wild-type p53 samples. However, due to the limited source of clinical samples, this pilot study requires validation.

In conclusion, in the present study, we found that the regulatory mechanism controlling CTSL expression may be associated with mutations in the p53 gene, revealing that mut-p53 may regulate the expression of CTSL through interactions with Egr-1/p300 and suggesting that CTSL may be a possible participant of mut-p53 GOF.

Acknowledgments

The authors sincerely thank Dr. Tan Caihong for providing us with colon cancer tissues and breast cancer tissues specimens.

Authorship Contributions

Participated in research design: Lin, Liang.
Contributed new reagents or analytic tools: Lin, Liang.
Conducted experiments: Xiong, Zhu, Liu, Zhao, Shen, Zuo.
Performed data analysis: Xiong, Zhu.
Wrote or contributed to the writing of the manuscript: Xiong, Zhu.

References

Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, and Piaggio G (2006) Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. *Cancer Cell* **10**:191–202.

Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, and Berger SL (2001) Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. *Mol Cell* **8**:1243–1254.

Breaux M, Lewis K, Valanejad L, Iakova P, Chen F, Mo Q, Medrano E, Timchenko L, and Timchenko N (2015) P300 regulates liver functions by controlling p53 and C/EBP family proteins through multiple signaling pathways. *Mol Cell Biol* **35**:3005–3016.

Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, and Mann M (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. *Science* **325**:834–840.

de Belle I, Huang RP, Fan Y, Liu C, Mercola D, and Adamson ED (1999) p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis. *Oncogene* **18**:3633–3642.

Duan W, Gao L, Kalvala A, Aguila B, Brooks C, Mo X, Ding H, Shilo K, Otterson GA, and Villalona-Calero MA (2019) Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice. *Int J Cancer* **145**:2418–2426.

Fei Y, Xiong Y, Shen X, Zhao Y, Zhu Y, Wang L, and Liang Z (2018) Cathepsin L promotes ionizing radiation-induced U251 glioma cell migration and invasion through regulating the GSK-3β/CUX1 pathway. *Cell Signal* **44**:62–71.

Hashimoto Y, Kondo C, Kojima T, Nagata H, Moriyama A, Hayakawa T, and Katunuma N (2006) Significance of 32-kDa cathepsin L secreted from cancer cells. *Cancer Biother Radiopharm* **21**:217–224.

Katara R, Mir RA, Shukla AA, Tiwari A, Singh N, and Chauhan SS (2010) Wild type p53-dependent transcriptional upregulation of cathepsin L expression is mediated by C/EBPα in human glioblastoma cells. *Biol Chem* **391**:1031–1040.

Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY, Kim CH, Park HG, Han SI, and Kang HS (2017) Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. *Mol Cancer* **16**:10.

Li ZL, Liang S, Wang ZC, Li YB, Guo CX, Fang F, Gong SL, and Lin CH (2014) Expression of Smac induced by the Egr1 promoter enhances the radiosensitivity of breast cancer cells. *Cancer Gene Ther* **21**:142–149.

Liu J, Grogan L, Nau MM, Allegra CJ, Chu E, and Wright JJ (2001) Physical interaction between p53 and primary response gene Egr-1. *Int J Oncol* **18**:863–870.

Magni M, Buscemi G, Maita L, Peng L, Chan SY, Montecucco A, Delia D, and Zannini L (2019) TSPYL2 is a novel regulator of SIRT1 and p300 activity in response to DNA damage. *Cell Death Differ* **26**:918–931.

Monteith JA, Mellert H, Sammons MA, Kuswanto LA, Sykes SM, Resnick-Silverman L, Manfredi JJ, Berger SL, and McMahon SB (2016) A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction. *Mol Oncol* **10**:1207–1220.

Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, et al. (2009) Mutant p53 drives invasion by promoting integrin recycling. *Cell* **139**:1327–1341.

Navab R, Pedraza C, Fallavollita L, Wang N, Chevet E, Auguste P, Jenna S, You Z, Bikfalvi A, Hu J, et al. (2008) Loss of responsiveness to IGF-I in cells with reduced cathepsin L expression levels. *Oncogene* **27**:4973–4985.

Orgad S, Goldfinger N, Cohen G, Rotter V, and Solomon B (2005) Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein. *FEBS Lett* **579**:5609–5615.

Peng WX, Wan YY, Gong AH, Ge L, Jin J, Xu M, and Wu CY (2017) Egr-1 regulates irradiation-induced autophagy through Atg4B to promote radioresistance in hepatocellular carcinoma cells. *Oncogenesis* **6**:e292.

Rousselet N, Mills L, Jean D, Tellez C, Bar-Eli M, and Frade R (2004) Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. *Cancer Res* **64**:146–151.

Sauer L, Gitenay D, Vo C, and Baron VT (2010) Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. *Oncogene* **29**:2628–2637.

Silverman ES, Du J, Williams AJ, Wadgaonkar R, Drazen JM, and Collins T (1998) cAMP-response-element-binding-protein-binding protein (CBP) and p300 are transcriptional co-activators of early growth response factor-1 (Egr-1). *Biochem J* **336**:183–189.

Sriraman V and Richards JS (2004) Cathepsin L gene expression and promoter activation in rodent granulosa cells. *Endocrinology* **145**:582–591.

Urbanelli L, Trivelli F, Ercolani L, Sementino E, Magini A, Tancini B, Franceschini R, and Emiliani C (2010) Cathepsin L increased level upon Ras mutants expression: the role of p38 and p44/42 MAPK signaling pathways. *Mol Cell Biochem* **343**:49–57.

Wang W, Long L, Wang L, Tan C, Fei X, Chen L, Huang Q, and Liang Z (2016) Knockdown of Cathepsin L promotes radiosensitivity of glioma stem cells both in vivo and in vitro. *Cancer Lett* **371**:274–284.

Wang W, Xiong Y, Ding X, Wang L, Zhao Y, Fei Y, Zhu Y, Shen X, Tan C, and Liang Z (2019) Cathepsin L activated by mutant p53 and Egr-1 promotes ionizing radiation-induced EMT in human NSCLC. *J Exp Clin Cancer Res* **38**:61.

Xiong Y, Ji W, Fei Y, Zhao Y, Wang L, Wang W, Han M, Tan C, Fei X, Huang Q, et al. (2017) Cathepsin L is involved in X-ray-induced invasion and migration of human glioma U251 cells. *Cell Signal* **29**:181–191.

Yang N, Wang P, Wang WJ, Song YZ, and Liang ZQ (2015) Inhibition of cathepsin L sensitizes human glioma cells to ionizing radiation in vitro through NF-κB signaling pathway. *Acta Pharmacol Sin* **36**:400–410.

Zagurovskaya M, Shareef MM, Das A, Reeves A, Gupta S, Sudol M, Bedford MT, Prichard J, Mohiuddin M, and Ahmed MM (2009) EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. *Oncogene* **28**:1121–1131.

Zhang QQ, Wang WJ, Li J, Yang N, Chen G, Wang Z, and Liang ZQ (2015) Cathepsin L suppression increases the radiosensitivity of human glioma U251 cells via G2/M cell cycle arrest and DNA damage. *Acta Pharmacol Sin* **36**:1113–1125.

Zhang W and Chen S (2001) EGR-1, a UV-inducible gene in p53(-/-) mouse cells. *Exp Cell Res* **266**:21–30.

Address correspondence to: Fang Lin, Soochow University, Suzhou 215000, China. E-mail: linfang-1@suda.edu.cn; or Zhong-qin Liang, Professor, Soochow University, Suzhou 215000, China. E-mail: liangzhongqin@suda.edu.cn